A Phase II Study of Additional Four-Week Chemotherapy With Capecitabine During the Resting Periods After Six-Week Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
Annals of Coloproctology
;
: 192-197, 2013.
Article
in English
| WPRIM
| ID: wpr-135304
ABSTRACT
PURPOSE:
The aim of this study is to evaluate the efficacy and the safety of additional 4-week chemotherapy with capecitabine during the resting periods after a 6-week neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced rectal cancer.METHODS:
Radiotherapy was delivered to the whole pelvis at a total dose of 50.4 Gy for 6 weeks. Oral capecitabine was administered at a dose of 825 mg/m2 twice daily for 10 weeks. Surgery was performed 2-4 weeks following the completion of chemotherapy.RESULTS:
Between January 2010 and September 2011, 44 patients were enrolled. Forty-three patients underwent surgery, and 41 patients completed the scheduled treatment. Pathologic complete remission (pCR) was noted in 9 patients (20.9%). T down-staging and N down-staging were observed in 32 patients (74.4%) and 33 patients (76.7%), respectively. Grade 3 to 5 toxicity was noted in 5 patients (11.4%). The pCR rate was similar with the pCR rates obtained after conventional NCRT at our institute and at other institutes.CONCLUSION:
This study showed that additional 4-week chemotherapy with capecitabine during the resting periods after 6-week NCRT was safe, but it was no more effective than conventional NCRT.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pelvis
/
Rectal Neoplasms
/
Polymerase Chain Reaction
/
Neoadjuvant Therapy
/
Deoxycytidine
/
Drug Therapy
/
Chemoradiotherapy
/
Capecitabine
/
Fluorouracil
Limits:
Humans
Language:
English
Journal:
Annals of Coloproctology
Year:
2013
Type:
Article
Similar
MEDLINE
...
LILACS
LIS